Peri-Transplant Ruxolitinib Leads to Low GVHD Incidence in Myelofibrosis - OncLive
Key claim: Peri-transplant ruxolitinib use is associated with low graft-versus-host disease (GVHD) incidence in myelofibrosis patients undergoing allogeneic stem cell transplant.
Abstract
OncLive reported on April 2nd, 2026 that peri-transplant ruxolitinib leads to low GVHD incidence in myelofibrosis, and covered recent trial data on emerging therapies.
Why this matters
GVHD remains a major driver of non-relapse mortality after allo-HSCT for myelofibrosis, and ruxolitinib’s immunomodulatory effects offer a way to leverage a drug already used for pre-transplant bridging into a GVHD-prevention role. If confirmed, this reshapes the bridging decision from a purely spleen/symptom-control question into a combined disease-control plus immunoprophylaxis strategy, potentially influencing conditioning choice and standard GVHD prophylaxis backbones.